Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea

Published:2024 Issue:5 Volume:65 Page:435
ISSN:2466-0493
Container-title:Investigative and Clinical Urology
language:en
Short-container-title:Investig Clin Urol

Author:

Kim Gang Kyu¹^ORCID,Jo Young Heun¹^ORCID,Lee Jongsoo¹^ORCID,Han Hyun Ho¹^ORCID,Ham Won Sik¹^ORCID,Jang Won Sik¹^ORCID,Heo Ji Eun¹^ORCID

Affiliation:

1. Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.

Publisher

XMLink

Link

https://icurology.org/pdf/10.4111/icu.20240047

Reference20 articles.

1. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020

2. International Variations in Bladder Cancer Incidence and Mortality

3. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

4. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

5. Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP